C4 Therapeutics Inc (NAS:CCCC)
$ 5.68 -0.29 (-4.86%) Market Cap: 390.82 Mil Enterprise Value: 222.30 Mil PE Ratio: 0 PB Ratio: 1.51 GF Score: 53/100

C4 Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion Transcript

Feb 21, 2023 / 05:00PM GMT
Release Date Price: $5.75 (-5.27%)
Derek Archila
Wells Fargo - Analyst

All right. We're on to our next panel here with the Wells Fargo TPD summit. My name is Derek Archila. I'm one of the senior biotech analysts here at Wells. With me, I have Stew Fisher from C4 Therapeutics and Peggy Scherle from Prelude Therapeutics to discuss our next topic -- or our panel topic, key targets for TPD and oncology and potential combo strategy.

So, Stew and Peggy, thank you so much for joining us.

Peggy Scherle
Prelude Therapeutics Incorporated - Chief Scientific Officer

Thank you for inviting us.

Stew Fisher
C4 Therapeutics, Inc. - Chief Scientific Officer

Thank you, Derek.

Derek Archila;Peggy Scherle
Wells Fargo - Analyst;Prelude Therapeutics Incorporated - Chief Scientific

All right. So maybe to start off, I'll turn it over to Peggy to just introduce herself, her background, and also just a little bit about how Prelude's kind of approaching TPD and what they're working on.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot